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Abstract
Background: Women living with HIV are at increased risk to be co-infected with HPV, persistent high-risk (HR)
human papillomavirus (HPV) infection and increased HR HPV viral load, which make them more at risk for cervical
cancer. Despite their inherent vulnerability, there is a scarcity of data on potential high risk (pHR) and HR HPV
genotypes in HIV- infected women with cervical dysplasia and HPV-type specific viral load in this population in Sub
Saharan Africa.
The aim of this analysis of HIV-infected women was to explore the virological correlates of high-grade cervical
dysplasia (CIN 2+) in HIV-infected women, thereby profiling HPV genotypes.
Method: This analysis assesses baseline data obtained from a cohort study of 74 HIV-infected women with
abnormal cytology attending a Comprehensive Care Centre for patients with HIV infection in Mombasa, Kenya.
Quantitative real-time PCR was used for HPV typing and viral load.
Results: CIN 2 was observed in 16% (12/74) of women, CIN 3 in 23% (17/74), and, invasive cervical carcinoma (ICC)
in 1% (1/74) of women. In women with CIN 3+, HPV 16 (44%), HPV 56 (33%), HPV 33 and 53 (HPV 53 (28%) were
the most prevalent genotypes. HPV 53 was observed as a stand-alone HPV in one woman with ICC.
A multivariate logistic regression adjusting for age, CD4 count and HPV co-infections suggested the presence of
HPV 31 as a predictor of CIN 2+ (adjusted odds ratio [aOR]:4.9; p = 0.05; 95% (Confidence Interval) [CI]:1.03–22.5).
Women with CIN2+ had a significantly higher viral log mean of HPV 16, (11.2 copies/ 10,000 cells; 95% CI: 9.0–13.4)
than with CIN 1.
Conclusion: The high prevalence of HPV 53 in CIN 3 and as a stand-alone genotype in the patient with invasive
cervical cancer warrants that its clinical significance be further revisited among HIV-infected women. HPV 31, along
with elevated means of HPV 16 viral load were predictors of CIN 2 + .
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Background
Kenya is home to the world’s fourth-largest HIV epi-
demic in the world. In 2013, an estimated 1.6 million
people were living with HIV and roughly 57,000 people
died from AIDS-related illnesses [1]. Cervical carcinoma,
an AIDS-related cancer, is the most common female
cancer in sub-Saharan Africa; [2] it has become the sec-
ond most prevalent cancer among women in Kenya,
after breast cancer, and its incidence is increasing [3].
Distinct precancerous stages or pre-invasive precursor
lesions called cervical intraepithelial neoplasia (CIN), or
dysplasia can be discriminated before becoming invasive
cervical cancer (ICC). CIN can be histologically graded
into mild dysplasia (CIN 1), moderate dysplasia (CIN 2),
and severe dysplasia to carcinoma in situ (CIN 3) [4].
Human Papilloma Viruses (HPV), a sexually transmit-
ted DNA virus are double-stranded DNA viruses,
considered the primary etiological agents in cervical
intraepithelial neoplasia and cancers. “High-risk”, (HR)
include HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59,
68 and due to lack of evidence of biological activity in
tumour tissues, HPV26, 53, 66, 67, 70, 73, and 82 are
classified as probably or possibly high risk [5].
It is well recognized that among the 15 HR HPV geno-
types, HPV 16 and HPV 18 confer the greatest risk for
CIN 2 or worse because these two genotypes are associ-
ated with approximately two thirds of all invasive cervical
carcinomas [6]. Several countries, including Kenya, have
licensed and adopted the bivalent HPV vaccine
(Cervarix™) that protects against HPV genotypes 16 and
18 and the quadrivalent vaccine (Gardasil™) that protects
against HPV genotypes 6, 11, 16 and 18 [7]. In 2014, a
nonavalent vaccine, not yet commercialized in Kenya,
containing the most frequently detected types in ICC
worldwide, HPV types 31, 33, 45, 52, and 58 antigens, [8]
will have direct implications for cervical cancer incidence
and prevention in all regions of the world with the poten-
tial to prevent almost 90% of ICC cases worldwide.
If viral persistence is established, a variety of host cofac-
tors may act upon the immune system and the tissue
microenvironment in the cervix to induce development of
cervical lesions. [9] A relationship has been established
between HIV immunosuppression and multiple HPV in-
fection, [10, 11] which has been attributed to the inability
to clear HPV infections and to reactivate latent HPV
infections, [10, 12–14]. Moreover, certain viral risk fac-
tors may also play a role in establishing viral persist-
ence. It has been suggested that high HPV viral load
may be aetiologically associated with cervical disease
pathogenesis, although studies have yielded conflicting
results. [15–20].
Moreover, epidemiological knowledge of potential high-
risk (pHR) HPV types is limited, mainly because commer-
cial molecular assays focus on HR HPV genotypes. Data
on pHR genotypes in HIV-infected women are even scar-
cer, although it can be hypothesized that they might play a
role in HPV related diseases in HIV positive women
[21, 22]. This can be attributed to the fact that HIV in-
fected women harbor a higher prevalence and broader
range of HR HPV, and HPV 16 does not figure as
prominently in HIV positive women. [23, 24].
Our analysis purported to test our two a priori
hypotheses: first that single pHR and HR HPV genotypes
in HIV-infected women are not independent predictors of
factors of CIN 2+, but involve synergistic mechanisms,
and second that HPV 16 viral load may be correlated with
CIN 2+. The objectives of this secondary analysis were to
determine the most prevalent genotype-specific distribu-
tion of HPV among women with CIN 2+, and to assess
whether specific pHR and HR HPV genotypes and their
respective viral load are associated with CIN 2 + .
Methods
To examine the epidemiology of type-specific HPV
infections, we carried out a cross-sectional analysis of all
74 HIV-infected women. This cross-sectional analysis
based on primary data collection and record reviews ad-
hered to the methodological guidelines recommended in
the STROBE document on observational studies [25].
Between November 2005 and April 2006, women at-
tending the Comprehensive HIV Care Centre (CCC) at
Coast Provincial General Hospital in Mombasa, Kenya
were informed about the study and were offered on site
cervical cancer screening with conventional Pap smear,
in addition to a general medical examination and routine
blood tests, including CD4 cell count. Women were en-
rolled if they were HIV positive and diagnosed with squa-
mous intra-epithelial lesions (SIL) by Pap smear, were
between 20 and 50 years of age, not pregnant and did not
have a history of hysterectomy or cervical cancer. Cervical
sampling for HPV testing was done. During the enrolment
visit, socio-demographic data were collected.
Written informed consent was obtained from all
participants. Illiterate women elected a person who
signed on their behalf after thorough explanation.
Ethical approval for the study was given by the Ethics
Committee of Ghent University Hospital and from the
Ethics and Research Committee of the Kenyatta National
Hospital (Ref number: Ref: KNH-ERC/01/3618). Six
hundred HIV infected women were tested to reach a
cohort of 74 HIV women with abnormal cytology.
Biologic specimens
Blood plasma samples were taken and a gynaecological
examination was done with speculum insertion, prior to
collection of endocervical and high vaginal swabs. Cer-
vical samples were collected using a cervix brush (Cer-
vex-brush®, Rovers®, Oss, The Netherlands), and cervical
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cytology was assessed with conventional Papanicolaou
(Pap) smears. Histology of the biopsy specimens were
processed and read by a qualified histopathologist. An
external cytopathologist provided quality control by
reviewing all cases. A diagnosis to each case was
assigned according to the Bethesda 2001 criteria [26].
The cervix brush tips were preserved in a liquid-based
cytology collection medium (SurePath®, Tripath Imaging
Inc., Burlington, North Carolina, USA) and stored at 4 °
C and shipped to Belgium for HPV testing.
Sample
Samples were collected according to the method de-
scribed by Micalessi et al. 2012 [27]. Cervical cells were
collected into an ethanol-based preservative (Surepath
TM, Tripath Imaging, Burlington, NC, USA) using the
Cervex-Brush ® or Cervex-Brush ® Combi (Rovers Med-
ical Devices B.V., KV Oss, The Netherlands), and were
processed into thin-layer LBC preparations using the
fully robotic Autocyte PREP system (Tripath Imaging,
Burlington, NC, USA) [28]. Upon finalizing the LBC
preparations, 800 μL of the remaining cell suspension
was used for DNA extraction.
HPV DNA extraction, detection and typing
HPV testing was done as described by Depuydt et al.
(2006) in an accredited laboratory (ISO certification:
ISO15189)[29]. Briefly, HPV DNA was extracted from exfo-
liated cervical cells using the standard proteinase K-based
digestion protocol. Cells were incubated with proteinase K
solution (100 μg/ml) for three hours at 55 °C. DNA was
then further purified by spin column chromatography.
HPV types were determined using a series of real-time PCR
reactions with specific primers and TaqMan® (Invitrogen,
La Jolla, USA) probes for HR- HPV types 16, 18, 31, 33, 35,
39, 45, 51, 52, 56, 58, 59, 68, [30] including the pHR HPV
genotypes 53 and 66. Low-risk HPV types 6, and 67 were
also detected. HPV viral load was detected by the use of
HPV type-specific real-time TaqMan PCR assays.
Assays were normalized to a reference gene. A calibrator
was included in every run and a standard curve was used
to convert the signal to viral load. Detection limits were
described by Micalessi et al. (2012) for each primer or
probe set [27].
A standard national testing algorithm was used for
HIV diagnosis using rapid immunoassays: Uni-Gold™
Recombigen® HIV (Trinity Biotech plc, Bray, Ireland)
and Determine® HIV-1/2 (Abbott Japan co Ltd, Minato-
Ku, Tokyo, Japan). In the case of indeterminate results,
an enzyme-linked immunosorbent assay was used to
confirm HIV status. CD4 count was performed using the
Becton Dickinson automated FACS count system [31].
Cervicitis was diagnosed from inflammatory cells by
means of microscopic evaluation.
Statistical analysis
Data were checked and cleaned as per standard pro-
cesses without substantial implications to the data, and
analysis was undertaken using STATA version 12 (Cor-
poration, College Station, TX, USA).
We first described the distribution of pHR and HR
HPV types observed among women with > CIN 2, CIN
2, CIN 3 and ICC.
Women over 30 years have a higher risk of abnormal cy-
tology, hence, age was dichotomized into two categories,
≥30 years and < 30 years. CD4 cell count was transformed
into categories including CD4 < 200 cells/μl and CD4 ≥
200 cells/μl. This breakdown was used to assess severe
immunosuppression. The number of pHR and HR HPV
co-infections was treated both as a categorical variable, no
HPV, one HPV and two or more HPV co-infections. As
the outcome of interest, patients’ histology result was
dichotomized into lower than CIN2 and CIN 2+. For the
univariate analysis, a logistic regression was fitted to meas-
ure the strength of the association between pHR and HR
HPV genotype separately and CIN 2+. A multivariable lo-
gistic regression analysis was performed to simultaneously
control for potential confounders, including age, low CD4
count, and the presence of co-infections.
Based on women with CD4 count < 200 being more at
risk for abnormal cytology, we tested this variable as a
potential effect modifier. We fitted a regression model to
assess the association between pHR and HR HPV
genotypes on CIN2+; in the same model, we assessed
the potential role of confounding and/or interaction of
age and CD4 count. Statistical significance of an odds
ratio (OR) was considered at p ≤ 0.05.
The log of the pHR/HR HPV viral load was taken as
the data were not normally distributed.
Results
Characteristics of the population
This study consisted of 74 HIV+, non-pregnant women
with an abnormal cytology, of which 81% (60/74) were
on HAART. Our study population had a mean age of
34.2, and 73% of women were 30 years of age and older.
The median CD4 count was 236 cells/μl [interquartile
range (IQR) 158–374], and 35% had CD4 count of 200
cells/μl or lower. The median age at first sexual inter-
course was 18 years (IQR = 15.5–20), and the median
number of sex partners was 2 (IQR: 1–4).
Prevalence of cervical and histological abnormalities
LSIL was detected in 43/74 (58%), Atypical Squamous
cells of undetermined significance (ASC-US) in 12/74
(16%), Atypical Squamous Cells cannot rule Out High-
Grade Squamous Intra-epithelial Lesion (ASC-H) in 3/
74 (4%), (HSIL) in 15/74 (20%) and 1/74 was inconclu-
sive (1%).
Menon et al. Virology Journal  (2018) 15:54 Page 3 of 8
Histological results in the 74 women with cytological
abnormalities were CIN 1 in 58% (41/74), CIN 2 in 16%
(12/74), CIN 3 in 23% (17/74), and one participant (1/
74) had invasive cervical carcinoma. Cervicitis was de-
tected in 15% (11/74) and normal histology in 4% (3/74).
Two (3%) biopsies were inconclusive. Overall, 30 (40.5%)
women had a cytology of CIN2+ (CIN2, CIN3 and ICC
combined).
Prevalence of pHR and HR HPV genotypes
To assess the prevalence of, potential high risk (pHR)
and high-risk (HR) HPV genotypes in the 74 HIV+
women with abnormal cytology, we assayed for specific
genotypes listed in Table 1 by qPCR. In our study, 48
harbored (65%) at least one pHR/HR HPV genotype.
The median number of concurrent HR HPV genotype
infections was two (IQR: 2–4).
Among the 30 women with CIN 2+, over half of
women (57%) had either HPV 16 or HPV 18 infection.
The combined prevalence of intermediate HPV risk
types in CIN 2+ was 30%, of which HPV 53 represented
(7/30) 23% and HPV 66 (2/30) 7%. In women with CIN
3+, HPV 16 8/18 (44%), HPV 56 6/18 (33%), HPV 33
and 53 HPV 53 5/18 (28%) were the most prevalent ge-
notypes (Table 1).
HPV correlates of CIN 2+
Only one genotype, HPV 31, was found to be statistically
significant in association with CIN 2+ adjusted for CD4
count, age and co-infections, (AOR = 4.9, 95%CI: 1.1–
22.6). No interaction with CD4 count and age was noted
(Table 2).
We found a non-significant inverse association
between HPV 53 and CIN 2+, and a significant inverse
effect against HPV 66 when adjusted for co-infection
(Table 3). Seventy-three percent (22/30) of women with
CIN 2+ harbored 2 or more pHR and HR HPV geno-
types. A univariate logistic regression yielded a statisti-
cally non-significant association (OR: 1.9; p = 0.2; CI:
0.7–5.3) between CIN 2+ and multiple pHR and HR
HPV genotypes (Table 3).
To assess the specific pHR/HR HPV load as a type-
dependent risk marker for CIN 2+, we measured the log
viral load copies/103 cells for specific genotypes in the
74 HIV+ women. Among the 30 women with CIN 2+,
HPV 16 and its phylogenetically related HPV 31 and 33
were found to have the highest mean viral load, with
HPV 16 having a mean of 11.2 (9.0–13.4) (Table 3).
Discussion
We observed a combined HPV 16 and HPV 18 prevalence
of 57% in women with CIN 2+ and a prevalence of pHR
HPV genotypes of 30%. In line with recent findings of a
meta-analysis on HPV distribution in HIV-infected
women disaggregated by cytological status in Africa, we
found a higher prevalence of HPV 16 in women with CIN
3 (56%) than CIN 2 (25%), although our percentage for
CIN 3 was higher than the one reported (41%–47%) [32].
Contrary to our first hypothesis, our data do not suggest
a significant association between multiple pHR/HR HPV
infections and CIN 2+. This study suggests that HPV 31 is
the only independent predictor of CIN 2+, and an inverse
relationship was detected between HPV 66 and CIN 2+.
However, in agreement with our hypothesis, our study
suggests that HPV 16 viral load correlated with CIN 2+.
Our combined HPV 16 and HPV 18 prevalence of 61% in
CIN 3+ suggests the need for a wider protection that the
nonavalent vaccine would confer.
There is a presumed link between HIV-positivity and
the prevalence of multiple HPV infections [10, 11]. Our
non-significant association between 2 or more coinfec-
tions and CIN 2+ contrasts with findings of a recent
large study on multiple HPV infections in Costa Rica in
which 5871 young healthy women with multiple infec-
tions were at significantly increased risk of CIN 2+ when
compared with those with single infections [33].
Contrary to our hypothesis of required synergistic
mechanisms between pHR/HR HPV genotypes for
cervical cancer genesis, it may be that in our study
population with a low median CD4 count of 236 cells/μl
(IQR: 158–374), single pHR HPV genotypes are capable
of inducing cervical cancer genesis.
Our lack of association between pHR HPV genotypes
and CIN 2+ is in agreement with an observation made
Table 1 Prevalence of pHR and HR HPV genotypes and pairs
according to histological results
Histological results
HPV Genotype < CIN 2
(n = 44)
CIN 2
(n = 12)
CIN 3
(n = 18)
ICC
HPV 16 32% (14/44) 25% (3/12) 44%(8/18)
HPV 53 25% (11/44) 17% (2/12) 28% (5/18) 1
HPV 52 16% (7/44) 42% (5/12) 17% (3/18)
HPV 56 18% (8/44) 8% (1/12) 33% (6/18)
HPV 58 16% (7/44) 42% (5/12) 6% (1/18)
HPV 18 16% (7/44) 25% (3/12) 17% (3/18)
HPV 35 14% (6/44) 25% (3/12) 18% (4/18)
HPV 31 7% (3/44) 33% (4/12) 18% (4/18)
HPV 33 7% (4/44) 25% (3/12) 28% (5/18)
HPV 39 7% (3/44) 17% (2/12) 17% (3/18)
HPV 45 0% 8% (1/12) 11% (2/18)
HPV 59 2% (1/44) 8% (1/12) 11% (2/18)
HPV 66 20% (9/44) 8% (1/12) 9% (1/18)
HPV 68 7% (3/44) 0% (0/12) 9% (1/18)
Multiple HPV coinfection 60% (26/44) 83% (10/12) 67% (12/18)
Menon et al. Virology Journal  (2018) 15:54 Page 4 of 8
by Rahman et al. (2011) that infection with pHR HPV
genotypes in HSIL became non-significant when HIV
status was included in the multivariate analysis. In
women with CIN 3+, HPV 53 was the third most preva-
lent genotype. (28%) The stand-alone HPV 53 in the
only ICC case recorded is incongruent with those from a
recent study in Kenya, where pHR HPV genotypes were
only detected in low-grade lesion [34]. The woman with
ICC was severely immunocompromised and had a very
low CD4 count of 2 cells/μl, which we hypothesize may
make her more at risk for a potential oncogenic capacity
of a pHR HPV genotype.
When examining associations between specific pHR
and HR HPV genotypes and CIN 2+, a multivariate ana-
lysis suggested the presence of HPV 31 as an independ-
ent predictor of CIN 2+. Furthermore, a high number of
concomitant pHR and HR HPV infections in women
was observed in the presence of HPV 31.
Our finding suggesting that HPV 16 viral load may cor-
relate with the severity of lesions is congruent with those
found in the literature pertaining to sub Saharan Africa
[35, 36]. Notwithstanding, a high viral mean load found
for HPV 31 and 33 in women with CIN 2+, a statistically
significant association was not demonstrated for these HR
HPV genotypes. From an epidemiological perspective, this
finding suggests a higher replicative capacity for HPV 16,
which is known to be persistent, along with its phylogen-
etically related genotypes HPV 31 and 33 in HIV-infected
women with CIN 2+ and may result in an increased trans-
mission rate. As a corollary, this underscores the public
health impact of monitoring unvaccinated HIV-infected
women more regularly than once every three years as rec-
ommended by the WHO [37].
Our findings can be extrapolated to a HIV population
that is moderately to severely immunosuppressed and
has had few sexual partners within the region. The rela-
tively high median of concurrent pHR and HR HPV infec-
tions suggests an inability to either clear HPV infectious
or a propensity to reactivate latent HPV infections.
Table 2 Association between various pHR and HR HPV genotypes and CIN 2/+. Odds Ratios (OR) from logistic regression
Variables adjusted OR for CIN 2+ (95%CI): model 1 P-value adjusted OR for CIN 2+ (95%CI): model 2 P-value
Age 30 and above 0.9 (0.3–2.3) 0.8
pHR and HR co-infections prevalence 1.6 (0.6–4.5) 0.4
CD4 count < 200 2.2 (0.8–5.8) 0.2
HPV 16 1.3 (0.5–3.6) 0.6 1.2 (0.4–3.5) 0.7
HPV 18 1.2 (0.3–4.2) 0.8 1.1 (0.3–3.9) 0.9
HPV 31 5.0 (1.1–21.6) 0.03 4.9 (1.03–22.5) 0.05
HPV 33 3.0 (0.8–11.5) 0.1 2.9 (0.7–11.1) 0.1
HPV 35 1.6 (0.5–4.4) 0.5 1.4 (0.4–5.0) 0.6
HPV 39 2.6 (0.6–12.3) 0.2 2.4 (0.5–11.6) 0.3
HPV 51 1.7 (0.4–6.4) 0.4 1.6 (0.4–6.1) 0.5
HPV 52 1.6 (0.5–5.1) 0.5 1.3 (0.4–4.7) 0.6
HPV 53 0.6 (0.2–2.0) 0.4 0.5 (0.1–1.7) 0.3
HPV 56 1.6 (0.5–5.6) 0.4 1.4 (0.4–5.2) 0.6
HPV 58 1.0 (0.3–4.0) 1.0 1.0 (0.3–3.5) 1.0
HPV 66 0.2 (0.04–1.0) 0.06 0.2 (0.03–0.9) 0.04
HPV 68 0.5 (0.05–5.4) 0.4 0.2 (0.04–4.5) 0.5
Model 1: adjusted for CD4 count, age
Model 2: adjusted for CD4 count, age, and pHR and HR HPV coinfections
P-value from Likelihood Ratio Test
Table 3 Mean log viral load copies/ 103 cells per pHR and HR
HPV genotypes
pHR and HR
HPV genotypes
Mean VL copies
in CIN 1 (95% CI)
Mean VL copies
in CIN 2+ (95% CI)
P value
HPV 16 8.5(6.6–10.4) 11.2 (9.0–13.4) 0.05
HPV 18 7.1 (4.4–9.8) 6.4 (2.8–9.9) 0.7
HPV 31 6.2 (0–14.8) 10.4 (7.0–13.8) 0.1
HPV 33 9.5 (6.3–12.7) 11.4 (9.8–13.1) 0.1
HPV 35 11.1 (6.1–16.0) 8.5 (6.4–10.5) 0.2
HPV 39 9.2 (0.1–18.2) 7.8 (5.3–10.3) 0.5
HPV 45
HPV 51 9.8 (3.5–16.1) 9.3 (5.9–12.6) 0.8
HPV 53 6.0 (3.9–8.2) 3.4 (1.3–5.4) 0.07
HPV 56 11.0 (8.7–13.3) 9.1 (5.8–12.5) 0.3
HPV 58 8.1 (6.1–10.0) 8.3 (4.3–12.1) 0.9
HPV 66 6.4 (0–19.4) 8.9 (6.6–11.2) 0.3
HPV 68 6.0 (0–15) NA NA
Total pHR/HR HPV VL 10.7 (9.6–11.8) 11.8 (10.7–12.9) 0.2
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However, it is unknown how many sexual partners their
spouses have had, nor can a social desirability bias in
reporting sexual behavior be excluded.
Strength and limitations
A major strength of our study is that our samples have
been histopathologically confirmed. A recent systematic
review suggests that most studies on cervical dysplasia
on the continent, have cervical cytology as endpoints,
[38] which only has a clinical sensitivity between 55%–
65% for detection of histopathologically confirmed ‘true
disease status [39]. Furthermore, the real-time TaqMan
PCR assays we used for detecting HPV genotypes were
validated [40].
We recognize that our study has certain inherent
methodological limitations. The small sample size
compromised our power to assess correlates solely for
CIN 3, which is the best proxy for ICC, despite type
distribution in CIN 3 not being completely represen-
tative of cancer [32].
Additionally, the cross-sectional design, which does not
allow the fulfillment of the temporal criterion for causality,
bases its analysis on a single measure of pHR and HR
HPV viral load for prevalent infections at the baseline
screening phase, which may not be able to capture the
transient nature of pHR and HR HPV infections. Conse-
quently, it may not be possible to disentangle the risk
posed by recently acquired infections along with its ele-
vated viral load from viral load deriving from older
infections.
A further limitation related to a cross sectional study
design may be the lack of data concerning age of acqui-
sition of HIV infection, since it is possible this may have
occurred too late in life for some of the women in our
study to influence CIN 2+. Moreover, lack of data on
HIV viral load and on the recombinant strains present
in HIV-1 infected women, precludes us from fully ex-
ploring synergistic mechanisms between the two viruses.
Research gaps
The epidemiology of pHR HPV genotypes in HIV
women is still poorly characterized, as HPV 26, 53,
67, 70,73, and 82 are not included in any HPV DNA
screening protocols in sub Saharan Africa. Our find-
ings warrant that the potential carcinogenesis of HPV
53 be better elucidated, especially in severely im-
munosuppressed women. According to Padalko et al.
(2015) the role of pHR HPV genotypes will also need
to be assessed in the post vaccine era, in case type
replacement leads to pHR HPV genotypes becoming
more prevalent in ICC [41].
A systematic review and meta-analysis [42] found that
the bivalent vaccine from GlaxoSmithKline had better
cross protection against HPV 31 in persistent infection,
but that efficacy against persistent infections with type
31 appeared to decrease with longer follow-up, suggest-
ing a waning of cross-protection. It still remains to be
determined whether a cross protection can be extrapo-
lated to HIV-infected women and in the presence of
multiple HR HPV genotypes.
The kinetics of different genotype viral load must also
be assessed amidst, not only different levels of immuno-
suppression, but also in the presence of different levels
of HIV viral load, multiple pHR and HR HPV infections
and other concomitant sexually transmitted infections
harbored by HIV-infected women. This would help to
elucidate the aetiologic role of pHR and HR HPV viral
load in cervical dysplasia pathogenesis and determine
virological parameters to predict high-grade lesion in
HIV infected women in sub Saharan Africa.
Conclusion
Our small sample suggest a high prevalence of HPV 16,
53, 56 and 33 in women with CIN 3+. Furthermore, a
HPV 31 was found to be an independent predictor of
CIN 2+ and HPV 16 viral load significantly higher in
women with CIN 2/+.
Whether the available bivalent prophylactic vaccine
will be able to meet its objective of reducing cervical
cancer incidence by 70% may depend on the efficacy of
cross protection against HPV 31 in HIV-infected women
and the synergies between HPV genotypes in inducing
cervical cancer genesis. The high prevalence of non-
HPV 16 and 18 genotypes underscore the benefits of the
nonavalent vaccine within this population.
Our high prevalence of HPV 53 in CIN 3+ and as a
stand-alone HPV genotype in ICC, suggests a need for
enhanced HPV 53 detection and its incorporation into a
local screening protocol. Given the potential public
health impact of pHR HPV in HIV-infected women and
its exclusion from prophylactic vaccines, future research
efforts are needed to investigate the epidemiology of
these genotypes in HIV-infected women in the role of
cervical cancer genesis. Moreover, large protective
studies assessing the impact of the kinetics on different
genotype viral load in HIV infected women in sub
Saharan Africa, are needed to elucidate the tripartite re-
lationship between HIV viral load, CD4 count and pHR
and HR HPV viral load.
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